Long-term efficacy of radiofrequency ablation compared to surgical resection for the treatment of small hepatocellular carcinoma.
To compare the clinical efficacy of surgical resection (SR) and radiofrequency ablation (RFA) for the treatment of small hepatocellular carcinoma (SHC; ≥ 5 cm in diameter). The clinical and follow-up data for 88 patients with SHC, including 42 cases of SR and 46 cases of RFA, were analyzed. The mean follow-up time was 34.36 ± 16.93 (range 6-72) months. The 1-, 3- and 5-year tumor-free survival rates were 85.4, 40.9, and 29.2% for the SR group and 82.6, 27.7, and 16.4% for the RFA group (p=0.51). The mean tumor-free survival for the SR and RFA groups was 32.78 and 29.39 months (p=0.51), respectively. The cumulative survival rates were 100. 63.7, and 50.4% for the SR group and 100, 66.3 and 37.4% for the RFA group (p=0.67). The average survival time was 50.78 and 47.62 months (p=0.67) for the SR and RFA groups, respectively. We divided the tumors into a ≤ 3 cm diameter group and a 3-5 cm diameter group and found that the data for both groups were not statistically different. Cox multivariate analysis indicated that the number of tumors significantly affected overall survival (p=0.02) after the effects of various factors were excluded. The overall tumor-free survival and overall survival of the SR and RFA groups were not statistically different. RFA is safe and effective for the treatment of SHC, with a long-term efficacy similar to that achieved by SR. Therefore, RFA is a preferred treatment method for SHC.